Document:

Exhibit
10.7

 

AGREEMENT

 

AGREEMENT
dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood
Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut.

 

1.       Employment

 

The
Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and conditions set forth in this
Agreement.

 

 

2.       Term

 

The
employment of Vyas shall be for a period of three (3) years commencing on the date of their Agreement, renewable annually thereafter
upon unanimous approval of the Board of Directors, provided that either party can terminate the employment at any time, for any
reason, upon 90 days’ notice (the “Employment Period”).

 

 

3.
       Compensation

 

Vyas’
Compensation and Benefits are set forth in Appendix A.

 

 

4.       Duties.

 

Vyas’
Duties are set forth in Appendix A.

 

 

5.
       Extent of services.

 

Vyas
shall devote such time, attention, and energies to NanoViricides' business as necessary to perform the duties set forth in Schedule
A. The parties, in general, estimate that that such services shall require three (3) days per week.

 

 

6.
       Disclosure of information.

 

Vyas
acknowledges that NanoViricides' trade secrets, including chemical compounds, laboratory technology, and other proprietary information,
as may exist from time to time are valuable, special, and unique assets of NanoViricides’ business. During and after the
term of her employment, Vyas agrees not to disclose any information acquired by Vyas with respect to any and all confidential
and proprietary information of NanoViricides or NanoViricides’ business, and to maintain and follow reasonable procedures
to prevent unauthorized disclosure of or use of the confidential information and to prevent it from falling in to the public domain
or the possession of unauthorized persons. Vyas agrees that for a period of seven (7) years after termination of employment with
NanoViricides, she will hold all confidential and/or proprietary information in strict confidence and will not disclose such confidential
or proprietary information to any third party, except as expressly agreed to in writing by an officer of NanoViricides.

 

    

     

    

 

Notwithstanding
the above, confidential or proprietary information will not include information that is:

 

i)
Lawfully known or available to Vyas from a source other than an employee of NanoViricides or any related or affiliated company;

 

ii)
Already known to Vyas as shown by written records, before its disclosure;

 

iii)
Developed independently by Vyas without the use or consideration of or reference to the confidential or proprietary information
of NanoViricides; or

 

iv)
Within, or later falls within, the public domain, without breach of the Agreement by Vyas.

 

In
the event of a breach or threatened breach by Vyas of the provisions of the paragraph, NanoViricides shall be entitled to an injunction
restraining Vyas from disclosing, in whole or in part, such confidential or proprietary information or from rendering any services
to any person, form, corporation, association, or other entity to whom such confidential or proprietary information, in whole
or in part, has been disclosed or is threatened to be disclosed. Nothing herein shall be construed as prohibiting NanoViricides
from pursuing any other remedies available to NanoViricides for such breach or threatened breach, including the recovery of damages
from the Vyas. The provisions of the article are supplementary to the provisions of the Restrictive Covenant in Article 9.

 

 

7.
        Vacation

 

Vyas’
Vacation and Holiday schedule is set forth in Appendix A.

 

 

8.
        Termination

 

A.       Termination
by Vyas

 

Vyas
may terminate the agreement by providing NanoViricides with 90 days written notice of Vyas’s intent to terminate her employment
and stating the effective date of such termination.

 

    

     

    

  

B.       Termination
by NanoViricides

 

Without
cause, NanoViricides may terminate the Agreement at any time with 90 days notice to Vyas. However, should NanoViricides terminate
this Agreement without cause, the compensation set forth in Schedule A shall continue for the remaining terms of the Agreement.

 

C.       Surviving
Clause

 

Notwithstanding
any termination of the Agreement, whether with cause or without cause, all other provisions of the Agreement remain in full force
and effect.

 

 

9.
        Restrictive covenant.

 

A.
       If the employment of Vyas with NanoViricides shall be terminated for any reason, she shall
not provide any services to any competitor, client, or customer of NanoViricides, or any affiliate of NanoViricides then existing,
either as an employee, officer, or consultant, nor be associated as an employee, officer, partner of any firm engaged in substantially
similar research or drug development as NanoViricides, or any affiliate of NanoViricides the existing, for a period of one year
from the effective date of such termination. This restrictive covenant is intended to protect proprietary information and technology
disclosed to Vyas as a result of Vyas’ work, and in consideration of the contract.

 

B.
       For purposes of this Agreement, “proprietary information” shall mean any information
relating to the business of NanoViricides, or any entity in which NanoViricides has a controlling interest, that has not previously
been publicly released by duly authorized representatives of NanoViricides and shall include (but shall not be limited to) information
encompassed in all research plans, formulas, proposals, business plans, financial information, costs, pricing information, or
investor information and records, and all invention methods, concepts, or ideas used in or reasonably related to the business
of NanoViricides or any entity in which NanoViricides or its officers and shareholders have a controlling interest. Vyas agrees
to regard and preserve as confidential all proprietary information, whether she has such information in her memory or in writing
or other physical form. Vyas will not, without written authority from NanoViricides to do so, directly or indirectly, use for
her benefit or purposes, nor disclose to others, either during the term of her employment hereunder or thereafter, except as required
by the conditions of her employment hereunder, any proprietary information. Vyas agrees not to remove from the premises of NanoViricides
or any subsidiary or affiliate of NanoViricides, except as an employee of NanoViricides in pursuit of the business of NanoViricides
or any of its subsidiaries, affiliates or any entity in which NanoViricides has a controlling interest, or except as specifically
permitted in writing by NanoViricides any document or object containing or reflecting any proprietary information. Vyas recognizes
that all such documents and objects, whether developed by him or by someone else, are the exclusive property of NanoViricides.

 

    

     

    

 

C.
       All proprietary information and all of Vyas’ interest in patents, patent applications,
trade secrets, trademarks, inventions, customer lists, employee lists, procedure, technological innovation, copyrights, developments,
and processes hereafter to the end of the period of the employment hereunder developed by Vyas but at NanoViricides' expense are
considered automatically assigned to the NanoViricides. Vyas shall execute any and all such assignments and other documents and
take any and all such other action as NanoViricides reasonably requests in order to vest in NanoViricides all Vyas' rights, title
and interest in all of the aforesaid items, free and clear of any liens or encumbrances.

 

D.
       Vyas expressly agrees that the covenants set forth in this section are given to NanoViricides
in connection with the employment of Vyas by NanoViricides and that such covenants are intended to protect NanoViricides against
the competition by Vyas, within the terms stated, to the fullest extent deemed reasonable and permitted in law and equity. In
the event that the foregoing limitations upon the conduct of Vyas are beyond those permitted by law, such limitation, both as
to time and geographical area shall be deemed to be reduced in scope and effect to the maximum extent permitted by law.

 

 

10.
      Representations of Vyas.

 

Vyas
represents and warrants that neither the execution and delivery of this Agreement nor the performance of her duties hereunder
violates the provision of any other agreement to which he is a party or by which he is bound. Vyas further agrees to indemnify
NanoViricides for all damages in the event that this representation is breached.

 

 

11.
      Arbitration.

 

Any
controversy or claim arising out of, or relating to this Agreement, or the breach thereof, shall be settled by arbitration in
the State of Connecticut in accordance with the rules then obtaining of the American Arbitration Association, and judgment upon
the award rendered may be entered and enforced in any court having jurisdiction thereof. However, such arbitration provision shall
not act as a stay of NanoViricides’ right to seek a restraining order against Vyas’ actual or anticipatory breach
of this Agreement of anticipatory disclosure of confidential or proprietary information.

 

 

12.
      Notices.

 

Any
notice required or desired to be given under this Agreement shall be deemed given if in writing sent by certified mail to her
residence in the case of Vyas, or to its principal office in the case of NanoViricides.

 

    

     

    

  

13.
      Waiver of breach.

 

The
waiver by NanoViricides of a breach of any provision of this Agreement by Vyas shall not operate or be construed as a waiver of
any subsequent breach by Vyas. No waiver shall be valid unless in writing and signed by an authorized officer of NanoViricides.

 

 

14.
      Entire agreement.

 

This
Agreement contains the entire understanding of the parties. It may not be changed orally but only by an agreement in writing signed
by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.

 

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first written upon.

 

	 	Nanoviricides, Inc.
	.	 
	 	 
	 	/s/_______________________________
	 	By Anil R. Diwan, President
	 	Duly authorized
	 	 
	 	 
	 	 
	 	/s/_______________________________
	 	Meeta Vyas

 

    

     

    

 

Appendix
A

Duties,
Compensation, and Benefits

 

 

NanoViricides
reserves the right to change the compensation and benefit policies at any time upon thirty (30) days written notice to Vyas.

 

 

1.       Duties

 

Vyas
shall serve as Interim Chief Financial Officer, to perform the usual duties of said offices, and shall have responsibility, subject
to direction of the Board of Directors, for participating in the management and direction of NanoViricides' financial operations,
and shall perform such specific other tasks consistent with such position as may from time to time be assigned to her by the Board
of Directors. Vyas shall devote her business time to the performance of her duties hereunder, and shall devote her labor, skill,
attention, and best ability in a manner that will faithfully and diligently further the business and interests of NanoViricides.

 

 

2.       Compensation

 

A.       Base
Salary

 

As
compensation for Vyas' services hereunder during the Employment Period, the Company shall pay Vyas a base salary of One Hundred
Eight Thousand Dollars ($108,000), payable on a monthly basis.

 

B.      Series
A Preferred Stock

 

During
the employment Period, NanoViricides shall issue 9,000 shares of NanoViricides $0.001par value Series A Convertible Preferred
stock (the “Preferred Stock”) each month to Vyas:

 

The
Preferred Stock so received and vested hereunder shall not be sellable by Vyas during the pendency of this Agreement.

 

 

3.       Benefits

 

Vyas
is engaged as an independent contractor and, as such, is not entitled to direct company paid benefits. The provisions of this
paragraph are not intended to limit, interefere or terminate any existing benefits to which Vyas is entitled.Exhibit 10.16

 

 

	To	Thursday, September 26, 2019.

 

Attn:

 

	 	Re:	Waiver Letter Regarding Conversion of Series A Shares

 

Ladies and Gentlemen:

 

Reference is made to
that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”)
of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this letter
(this “Waiver Letter”) shall have the meanings assigned to such terms in the Designator.

 

1.                 Waiver
Provision. Section 5 of the Designation provides that the Holder may convert their Shares of Series A Preferred Stock,
at the Conversion Rate, upon a “Change of Control” of the Company as defined in the Certificate of Designation of
Series A stock.

 

2.                 Waiver. Holder hereby agrees to waive any and all conversion rights in the Designation until the earlier of: (a)
December 31, 2019, or (b) the date the Company amends its Articles of incorporation to increase its authorized number of shares
of Common Stock to not less than 150,000,000 shares (the “Authorized Increase”).

 

3.                 Company Covenants, Representations and Warranties. 

 

a.                 The Company shall use its best efforts to obtain shareholder approval for the Authorized Increase on or before December 31, 2019
pursuant to a duly called meeting at which the Board would recommend such approval. The Company hereby represents and warrants
that the Board has approved such Authorized Increase and the taking of all actions necessary or advisable to implement this Waiver,
and has determined that a simple majority in interest of the vote of all shareholders is sufficient to satisfy the shareholder
vote requirements for the Authorized Increase under applicable law or otherwise. Such approval shall not be amended or rescinded
without Holder’s approval.

 

b.                 While this waiver of conversion rights by the Holder is in effect, the Company shall not engage into any acts or events that would
trigger a conversion under the Certificate of Designation of Series A shares without consent of the Holder.

 

 

 

    Page 1
                                                                                      of 3

     

    

 

 

 

c.                 While this waiver of conversion rights by the Holder is in effect, the Company shall not engage into any act or acts, or enable
any events, that may have the effect of amending, modifying, changing, or canceling the Certificate of Designation of Series A
shares.

 

d.                 In the event that the Company does not increase its authorized number of shares of Common Stock to not less than 150,000,000 shares
(the “Authorized Increase”) on or before December 31, 2019, without limitation of any other remedies available to Holder,
the Company shall if requested by Holder negotiate promptly and in good faith with the Holder to replace the Series A certificates
with instruments of at least equal value, such value to be estimated as though there was no waiver in effect and as though the
Company had performed the Authorized Increase.

 

4.                 Acknowledgement. Except as expressly modified and superseded by this Amendment, the terms and provisions of this
Waiver Letter and any instruments executed in connection therewith are hereby ratified and confirmed and shall continue in full
force and effect.

 

a.                 Choice of Law. This Waiver Letter (including, but not limited to, the validity and enforceability hereof) shall be
governed by, and construed in accordance with, the laws of the State of Nevada.

 

5.                 Counterparts. This Waiver Letter may be executed by one or more of the parties hereto in any number of separate counterparts,
and all of such counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of this Waiver
Letter by electronic mail or facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.

 

[ Signature Page to Follow]

 

 

 

    Page 2
                                                                                      of 3

     

    

 

 

If the foregoing correctly
states your understanding with respect to the matters stated in this Waiver Letter, please acknowledge by signing in the space
provided below.

 

	 	Company:
	 	NANOVIRICIDES, INC.
	 	 	 
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 	 
	 	Holder:
	 	THERACOUR PHARMA, INC.
	 	 	 
	 	 	 
	 	By:  	 
	 	Name:
	 	Title:

 

 

    Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]